Avandia

Type: Product
Name: Avandia
First reported 4 hours ago - Updated 4 hours ago - 1 reports

Post-marketing surveillance of medicines: the Black Triangle scheme

By Paul EnglandThe European Medicines Agency (EMA) launched a new post-marketing surveillance system in the autumn called the ‘Black Triangle’ scheme. This follows a similar scheme in the UK, where the Commission on Human Medicines (CHM) and the Medicines ... [Published The Lawyer - 4 hours ago]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Scripps Florida Scientists Awarded $2 Million to Study Improvements in Anti-Diabetic Drug Design

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.1 million from the National Institutes of Health to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic ... [Published Fierce Biotech Research - Apr 22 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

The Right To A Speedy (Clinical) Trial

Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need to ... [Published Yahoo! Finance - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Scripps scientists win $2M research grant

Scripps Research Institute scientists in Jupiter won a $2.1 million grant to search for an anti-diabetes drug.The National Institutes of Health provided the five-year grant to a team led by Douglas Kojetin, an associate professor. They aim to create a ... [Published Business First of Buffalo - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 1 reports

Scientists awarded $2 million to study improvements in anti-diabetic drug design

PUBLIC RELEASE DATE: 16-Apr-2014JUPITER, FL, April 16, 2014 – Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.1 million from the National Institutes of Health to study the therapeutic potential of safer ... [Published EurekAlert! - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Mealey's PI/Product Liability - Avandia MDL Judge Says Ark. 'Illegal Extraction' Case Mooted By State's Settlement

PHILADELPHIA - A private Arkansas "illegal extraction" claim against GlaxoSmithKline PLC (GSK) for its marketing of the Avandia diabetes drugs is moot because the state attorney general has already settled identical claims, a Pennsylvania federal judge ... [Published Mealey - Apr 15 2014]
First reported Apr 12 2014 - Updated Apr 12 2014 - 1 reports

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

By Alliance for Natural HealthAn important new book by a recognized medical research expert describes Big Pharma as akin to the Mafia.In  an interview conducted by our colleagues at ANH-Europe , Dr. Peter C. Gøtzsche exposes the flaws of the drug approval ... [Published Health Impact News - Apr 12 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Missing safety risk emails draw $9bn Actos fine

A US jury has fined Takeda and Eli Lilly $9 billion (£5.4 billion) for causing a man’s bladder cancer with their diabetes drug Actos ( pioglitazone ). The verdict came down hard on the companies after the case unearthed evidence that Japanese company ... [Published RSC - Apr 11 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

Takeda fined record $6 bn over diabetes drug Actos; eli Lilly 3 bn

Takeda Pharmaceutical Co Ltd, Japan's largest drug firm, has been fined a record $6 billion in punitive damages by a US court over claims that it concealed cancer risks associated with its best-selling diabetes drug Actos.US pharmaceutical giant Eli Lilly, ... [Published domain-b - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Oramed Can Benefit As MannKind Opens The Diabetes Market For Novel Drugs

SummaryMannKind Corp.’s FDA panel approval for Afrezza can pave the way for greater physician acceptance of different ways to treat diabetes, ultimately benefitting Oramed. The diabetes drug industry is filled with examples of how innovative drug classes ... [Published Seeking Alpha - Apr 08 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Mealey's PI/Product Liability - Girardi Keese, GSK Agree To Arbitrate Avandia Dispute After Law Firm Is Enjoined

PHILADELPHIA - A day after a temporary restraining order (TRO) was entered against it, plaintiff law firm Girardi Keese on March 27 agreed to arbitrate a dispute it has with Avandia manufacturer GlaxoSmithKline LLC (GSK), according to a status report ... [Published Mealey - Mar 28 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Mealey's PI/Product Liability - GSK Can Seek Summary Judgment On Heart Failure Claims After 2007 Label Change

PHILADELPHIA - Avandia maker GlaxoSmithKline LLC (GSK) can file a motion for summary judgment against plaintiffs who claim that they developed congestive heart failure (CHF) after GSK changed Avandia's warning label in 2007, the Pennsylvania federal judge ... [Published Mealey - Mar 25 2014]

Quotes

" Massive corruption revealed to be at the core of many drug approvals " screamed the 2012 headline from Joseph Mercola, author of the widely read "world's #1 natural health website"
"This unexpected finding opens a lot of potential opportunities," Kojetin said. "We're looking to design a molecule that blocks both sites and can be used to probe what this alternative binding does on a molecular level—with the hope that this information will help us come up with a better drug model."
"It's possible that if we were to see a similar situation of a bigger magnitude, the FDA would pull back," he said. "But I think the science behind what FDA has done is so much more rigorous now, it's hard to see what that could be."
"These sessions were delivered by specialist healthcare professionals who, based on contracts signed with GSK, received payments appropriate to the scope of work as well as their level of knowledge and experience. The provision of sessions under this programme was agreed with the Polish healthcare centres" the statement said

More Content

All (70) | News (57) | Reports (0) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Post-marketing surveillance of medicines: the B... [Published The Lawyer - 4 hours ago]
Why Tamiflu is a success story [Published Australian Doctor - 18 hours ago]
Scripps Florida Scientists Awarded $2 Million t... [Published Fierce Biotech Research - Apr 22 2014]
The Right To A Speedy (Clinical) Trial [Published Yahoo! Finance - Apr 17 2014]
Scripps scientists win $2M research grant [Published Business First of Buffalo - Apr 17 2014]
Scientists awarded $2 million to study improvem... [Published EurekAlert! - Apr 16 2014]
New report finds Bydureon safest of new class o... [Published FiercePharma - Apr 16 2014]
Mealey's PI/Product Liability - Avandia MDL Jud... [Published Mealey - Apr 15 2014]
GSK under investigation after bribery scandal [Published Interactive Investor - Apr 14 2014]
Deadly Medicines and Organized Crime: How big p... [Published Health Impact News - Apr 12 2014]
Star obtains list of red-flagged drugs [Published Toronto Star Online - Apr 12 2014]
Missing safety risk emails draw $9bn Actos fine [Published RSC - Apr 11 2014]
Ben Goldacre eviscerates Roche and Tamiflu [Published PharmaGossip - Apr 11 2014]
What the Tamiflu saga tells us about drug trial... [Published Guardian.co.uk - Apr 10 2014]
Oramed Can Benefit As MannKind Opens The Diabet... [Published Seeking Alpha - Apr 08 2014]
Takeda fined USD6 billion over bladder cancer c... [Published Diabetes.co.uk - Apr 08 2014]
Takeda fined record $6 bn over diabetes drug Ac... [Published domain-b - Apr 08 2014]
Takeda and Lilly hit with $9 billion Actos dama... [Published Pharmafocus - Apr 08 2014]
Patient Handout: 7 Tips to Drop Excess Pounds w... [Published Diabetes in Control - Apr 06 2014]
Transvaginal Mesh Patient Awarded $1.2 Million ... [Published 4 Traders - Apr 04 2014]
7 steps to keeping your bones strong and health... [Published Washington Post - Mar 31 2014]
Relationship Between Cardiac Issues, Diabetes G... [Published American Journal of Managed Care - Mar 30 2014]
Time to hold ‘big pharma’ responsible, Tory MP ... [Published Toronto Star Online - Mar 29 2014]
FDA Lifts Restrictions on Rosiglitazone [Published American Journal of Nursing - Mar 29 2014]
Mealey's PI/Product Liability - Girardi Keese, ... [Published Mealey - Mar 28 2014]
Makings of a Wide Moat in Diabetes Care [Published Yahoo! Finance - Mar 28 2014]
Makings of a Wide Moat in Diabetes Care [Published Morningstar.com - Mar 28 2014]
Patent expiration, stagnant R&D spend seriously... [Published PharmaBiz - Mar 28 2014]
L.A. Times Article Has Incorrect Statements Aga... [Published BioPortfolio - Mar 26 2014]
Mealey's PI/Product Liability - GSK Can Seek Su... [Published Mealey - Mar 25 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Ben Goldacre eviscerates Roche and Tamiflu [Published PharmaGossip - Apr 11 2014]
Today we found out that Tamiflu doesn't work so well after all. Roche, the drug company behind it, withheld vital information on its clinical trials for half a decade, but the Cochrane Collaboration, a global not-for-profit organisation of 14,000 academics, ...
Statins aren't a wonder drug | Malcolm Kendrick [Published Comment is free | guardian.co.uk - Mar 23 2014]
The claims made for statins are overblown. They are not a cure for most of the major diseases afflicting western civilisation Statins are the most widely prescribed drugs in medical history. They appear to have effortlessly conquered heart disease. ...
Doctor Glaxo is here to teach you [Published PharmaGossip - Mar 17 2014]
GlaxoSmithKline Plc (GSK)  plans to hire doctors to educate their peers about its drugs instead of paying external speakers, a further change to its marketing practices following a record fraud settlement in the U.S.The drugmaker is also investing in ...
Reps on Safety Issues, or, the Sounds of Silence [Published Hooked: Ethics, Medicine, and Pharma - Feb 03 2014]
When writing in HOOKED about drug reps, I asserted that they seem to soft-pedal safety concerns, seldom mentioning any adverse reactions to their drugs. Unfortunately, the data at the time were restricted to one major study in France, so one could claim ...
It's a scandal drug trial results are still bei... [Published Comment is free | guardian.co.uk - Jan 05 2014]
Doctors like me can't give an informed view on the benefits of any treatment, let alone Tamiflu, because drugs firms aren't publishing all the evidence The Commons public accounts committee's report into the government's handling of the UK's £424m ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.